The DOI matches its Crossref record.
LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-Resistant Staphylococcus aureus
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) infections are a severe threat to public health. Antimicrobial peptides (AMPs) are novel and potential antimicrobials with specific antibacterial mechanisms. Our aim was to study the potential of LL37, FK16, and FK13 to enhance the anti-MRSA activity of antibiotics in vitro, particularly penicillin G and ampicillin. Our results showed that FK16 and FK13 have more synergistic inhibitory effects to MRSA strains when combined with penicillin G and ampicillin. In addition, AMPs exhibited strong membrane permeabilizing properties, and membrane permeabilizing effects can provide a possible explanation for the improved antibacterial effects of antibiotics, since permeabilizing AMPs have the potential to increase the access of antibiotics. To further study the electrostatic interactions among cationic AMPs with negatively charged bacteria, we measured the zeta potentials of three MRSA strains and also neutralized three MRSA strains with the addition of cationic AMPs. Further, we demonstrated the connection between membrane permeabilization and zeta potential neutralization. Finally, we treated MRSA strains with AMPs and characterized the MICs of penicillin G and ampicillin. FK16 was the most promising AMP among the three AMPs, since exposure to FK16 decreased the MICs of both penicillin G and ampicillin for all MRSA strains and also demonstrated more synergistic combinations when combined with antibiotics. AMP exposure and subsequent membrane permeabilization provide a possible pathway to re-sensitize drug-resistant bacteria to traditional antibiotics. Re-sensitization may help preserve the effectiveness of traditional antibiotics, thus providing a potential new strategy for fighting MRSA infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, S. aureus modifies its surface charge through the MprF protein, enabling it to repel cationic antimicrobial peptides like LL-37, thereby enhancing its survival in the nasal cavity [23].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 57
- Awad, 2009, Implementation of a methicillin-resistant Staphylococcus aureus (MRSA) prevention bundle results in decreased MRSA surgical site infections, Am. J. Surg., 198, 607, 10.1016/j.amjsurg.2009.07.010 · doi:10.1016/j.amjsurg.2009.07.010
- Fishovitz, 2014, Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus, IUBMB Life, 66, 572, 10.1002/iub.1289 · DOI · Paper page
- Macheboeuf, 2006, Penicillin binding proteins: Key players in bacterial cell cycle and drug resistance processes, FEMS Microbiol. Rev., 30, 673, 10.1111/j.1574-6976.2006.00024.x · DOI · Paper page
- Kocaoglu, 2013, Penicillin-binding protein imaging probes, Curr. Protoc. Chem. Biol., 5, 239, 10.1002/9780470559277.ch130102 · DOI
- Hartman, 1984, Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus, J. Bacteriol., 158, 513, 10.1128/jb.158.2.513-516.1984 · DOI · Paper page
- Cong, 2020, Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features, J. Adv. Res., 21, 169, 10.1016/j.jare.2019.10.005 · DOI · Paper page
- Gu, 2013, The emerging problem of linezolid-resistant Staphylococcus, J. Antimicrob. Chemother., 68, 4, 10.1093/jac/dks354 · DOI · Paper page
- Bababeygy, 2009, Rifampin and linezolid in the treatment of methicillin-resistant Staphylococcus aureus preseptal cellulitis, Ophthalmic Plast. Reconstr. Surg., 25, 227, 10.1097/IOP.0b013e3181a394ab · DOI
- Tyers, 2019, Drug combinations: A strategy to extend the life of antibiotics in the 21st century, Nat. Rev. Microbiol., 17, 141, 10.1038/s41579-018-0141-x · DOI · Paper page
- Cadena, 2011, Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 55, 5430, 10.1128/AAC.00706-11 · DOI
- Liu, 2020, Effect of tolerance on the evolution of antibiotic resistance under drug combinations, Science, 367, 200, 10.1126/science.aay3041 · DOI · Paper page
- Hegreness, 2008, Accelerated evolution of resistance in multidrug environments, Proc. Natl. Acad. Sci. USA, 105, 13977, 10.1073/pnas.0805965105 · DOI · Paper page
- Mohammad, 2015, Antimicrobial peptides and peptidomimetics-potent therapeutic allies for staphylococcal infections, Curr. Pharm. Des., 21, 2073, 10.2174/1381612821666150310102702 · DOI
- Halder, 2015, Alteration of Zeta potential and membrane permeability in bacteria: A study with cationic agents, SpringerPlus, 4, 672, 10.1186/s40064-015-1476-7 · DOI · Paper page
- Chan, 2006, Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action, Biochim. Biophys. Acta, 1758, 1184, 10.1016/j.bbamem.2006.04.006 · DOI · Paper page
- Lei, 2019, The antimicrobial peptides and their potential clinical applications, Am. J. Transl. Res., 11, 3919
- Assoni, 2020, Resistance mechanisms to antimicrobial peptides in gram-positive bacteria, Front. Microbiol., 11, 2362, 10.3389/fmicb.2020.593215 · DOI · Paper page
- Normark, 2002, Evolution and spread of antibiotic resistance, J. Intern. Med., 252, 91, 10.1046/j.1365-2796.2002.01026.x · DOI · Paper page
- Roemhild, R., and Andersson, D.I. (2021). Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathog., 17. · DOI
- Kahlenberg, 2013, Little peptide, big effects: The role of LL-37 in inflammation and autoimmune disease, J. Immunol., 191, 4895, 10.4049/jimmunol.1302005 · DOI · Paper page
- Sudheendra, 2006, LL-37, the only human member of the cathelicidin family of antimicrobial peptides, Biochim. Biophys. Acta (BBA) Biomembr., 1758, 1408, 10.1016/j.bbamem.2006.03.030 · DOI · Paper page
- Mahlapuu, 2014, Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: A randomized, placebo-controlled clinical trial, Wound Repair Regen., 22, 613, 10.1111/wrr.12211 · DOI · Paper page
- Lozeau, 2018, Concentration-dependent, membrane-selective activity of human LL37 peptides modified with collagen binding domain sequences, Biomacromolecules, 19, 4513, 10.1021/acs.biomac.8b00802 · doi:10.1021/acs.biomac.8b00802
- Han, 2022, New antimicrobial peptide-antibiotic combination strategy for Pseudomonas aeruginosa inactivation, Biointerphases, 17, 041002, 10.1116/6.0001981 · doi:10.1116/6.0001981
- Ridyard, K.E., and Overhage, J. (2021). The potential of human peptide LL-37 as an antimicrobial and anti-biofilm agent. Antibiotics, 10. · DOI · Paper page
- Wang, 2019, Design of antimicrobial peptides: Progress made with human cathelicidin LL-37, Antimicrob. Pept. Basics Clin. Appl., 1117, 215, 10.1007/978-981-13-3588-4_12 · DOI
- Li, 2006, Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region, J. Am. Chem. Soc., 128, 5776, 10.1021/ja0584875 · DOI · Paper page
- Mohamed, 2016, Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus, Sci. Rep., 6, 29707, 10.1038/srep29707 · DOI · Paper page
- Turner, 1998, Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob, Agents Chemother., 42, 2206, 10.1128/AAC.42.9.2206 · DOI · Paper page
- Mohammed, 2019, Cathelicidin-derived synthetic peptide improves therapeutic potential of vancomycin against Pseudomonas aeruginosa, Front. Microbiol., 10, 2190, 10.3389/fmicb.2019.02190 · DOI
- Geitani, R., Ayoub Moubareck, C., Touqui, L., and Karam Sarkis, D. (2019). Cationic antimicrobial peptides: Alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol., 19. · DOI
- Kondo, 1991, Susceptibility of methicillin-resistant Staphylococcus aureus to various antibiotics. Classification by aminoglycoside-modifying enzymes and antibiotics active against MRSA, Jpn. J. Antibiot., 44, 1211
- Ma, 2020, Contemporaneous Measurement of Outer and Inner Membrane Permeability in Gram-negative Bacteria, Bio-Protocol, 10, e3548, 10.21769/BioProtoc.3548 · DOI
- Rosenberg, 2019, Propidium iodide staining underestimates viability of adherent bacterial cells, Sci. Rep., 9, 6483, 10.1038/s41598-019-42906-3 · DOI · Paper page
- Lambert, 2002, Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria, J. Appl. Microbiol., 92, 46S, 10.1046/j.1365-2672.92.5s1.7.x · DOI · Paper page
- Maillard, 2021, Zeta potential beyond materials science: Applications to bacterial systems and to the development of novel antimicrobials, Biochim. Biophys. Acta (BBA) Biomembr., 1863, 183597, 10.1016/j.bbamem.2021.183597 · DOI
- Alves, 2010, Escherichia coli cell surface perturbation and disruption induced by antimicrobial peptides BP100 and pepR, J. Biol. Chem., 285, 27536, 10.1074/jbc.M110.130955 · DOI · Paper page
- Burgess, 2014, Amplified origins of antibiotic resistance, Nat. Rev. Genet., 15, 362, 10.1038/nrg3740 · DOI
- Azhar, 2017, Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus, J. Med. Microbiol., 66, 1328, 10.1099/jmm.0.000566 · doi:10.1099/jmm.0.000566
- Tian, Y., Li, T., Zhu, Y., Wang, B., Zou, X., and Li, M. (2014). Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China. BMC Microbiol., 14. · DOI
- Cui, 2003, Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus, J. Clin. Microbiol., 41, 5, 10.1128/JCM.41.1.5-14.2003 · DOI · Paper page
- Cui, 2021, Cell wall thickness and the molecular mechanism of heterogeneous vancomycin-intermediate Staphylococcus aureus, Lett. Appl. Microbiol., 72, 604, 10.1111/lam.13456 · doi:10.1111/lam.13456
- Field, 2016, Synergistic nisin-polymyxin combinations for the control of Pseudomonas biofilm formation, Front. Microbiol., 7, 1713, 10.3389/fmicb.2016.01713 · DOI
- Ejim, 2011, Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy, Nat. Chem. Biol., 7, 348, 10.1038/nchembio.559 · DOI · Paper page
- Swoboda, 2010, Wall teichoic acid function, biosynthesis, and inhibition, Chembiochem, 11, 35, 10.1002/cbic.200900557 · DOI · Paper page
- Brown, 2013, Wall teichoic acids of gram-positive bacteria, Annu. Rev. Microbiol., 67, 313, 10.1146/annurev-micro-092412-155620 · DOI · Paper page
- Giuliani, 2008, Antimicrobial peptides: Natural templates for synthetic membrane-active compounds, Cell. Mol. Life Sci., 65, 2450, 10.1007/s00018-008-8188-x · DOI · Paper page
- Nguyen, 2011, The expanding scope of antimicrobial peptide structures and their modes of action, Trends Biotechnol., 29, 464, 10.1016/j.tibtech.2011.05.001 · DOI · Paper page
- Sato, 2006, Peptide–membrane interactions and mechanisms of membrane destruction by amphipathic α-helical antimicrobial peptides, Biochim. Biophys. Acta (BBA) Biomembr., 1758, 1245, 10.1016/j.bbamem.2006.02.021 · DOI · Paper page
- Li, 2012, Overview on the recent study of antimicrobial peptides: Origins, functions, relative mechanisms and application, Peptides, 37, 207, 10.1016/j.peptides.2012.07.001 · DOI · Paper page
- Marks, L.R., Clementi, E.A., and Hakansson, A.P. (2012). The Human Milk Protein-Lipid Complex HAMLET Sensitizes Bacterial Pathogens to Traditional Antimicrobial Agents. PLoS ONE, 7. · DOI
- Mishra, 2016, Anti-staphylococcal biofilm effects of human cathelicidin peptides, ACS Med. Chem. Lett., 7, 117, 10.1021/acsmedchemlett.5b00433 · DOI
- Wiegand, 2008, Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances, Nat. Protoc., 3, 163, 10.1038/nprot.2007.521 · DOI · Paper page
- Cha, 2014, Synergistic effect between cryptotanshinone and antibiotics against clinic methicillin and vancomycin-resistant Staphylococcus aureus, Evid. Based Complement. Altern. Med., 2014, 450572, 10.1155/2014/450572 · DOI
- Li, 2021, Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens, Commun. Biol., 4, 31, 10.1038/s42003-020-01511-1 · DOI
- Ng, 2018, Rational design and synthesis of modified teixobactin analogues: In vitro antibacterial activity against Staphylococcus aureus, Propionibacterium acnes and Pseudomonas aeruginosa, Chem. A Eur. J., 24, 9136, 10.1002/chem.201801423 · DOI
- Kwon, 2019, Mechanism of action of antimicrobial peptide P5 truncations against Pseudomonas aeruginosa and Staphylococcus aureus, AMB Express, 9, 122, 10.1186/s13568-019-0843-0 · doi:10.1186/s13568-019-0843-0
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Han, W., & Camesano, T. A.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2023-09-01
- Volume
- 12
- Issue
- 9
- Pages
- 1398
- ISSN
- 2079-6382
- Cited by
- 12
- References
- 0
- Language
- en
- Funders
- ALDEN FELLOWSHIP from Worcester Polytechnic Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-Resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.3390/antibiotics12091398
- The paper
- Han, W., & Camesano, T. A. (2023). LL37-Derived Fragments Improve the Antibacterial Potential of Penicillin G and Ampicillin against Methicillin-Resistant Staphylococcus aureus. Antibiotics. https://doi.org/10.3390/antibiotics12091398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.